A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma

on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The efficacy and safety of lenalidomide (LEN) consolidation therapy and subsequent LEN maintenance therapy after high-dose therapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in patients with newly diagnosed symptomatic multiple myeloma (MM). Forty-one patients were enrolled and received high-dose dexamethasone (DEX) therapy as an initial induction. The patients who did not respond to the DEX therapy were further treated with four cycles of bortezomib plus DEX (BD) induction therapy. For patients who responded to BD, PBSC harvesting was scheduled following high-dose cyclophosphamide and filgrastim administration. After PBSC harvesting, high-dose chemotherapy of melphalan with auto-PBSCT was performed. One hundred days after auto-PBSCT, patients received consolidation therapy consisting two cycles of LEN plus low-dose DEX (Ld) and LEN maintenance therapy. Only one death occurred during mobilization therapy, but the protocol developed in this study was considered generally safe to provide. Overall response rates after consolidation and maintenance therapies were 73.7% and 81.6%, respectively. Two-year progression-free survival and overall survival were 76.3% and 92.1%, respectively. These observations suggest that LEN consolidation and maintenance therapy are effective and safe, and provide favorable response rates in patients with MM.

Original languageEnglish
Pages (from-to)107-114
Number of pages8
JournalInternational journal of hematology
Volume109
Issue number1
DOIs
Publication statusPublished - Jan 22 2019

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma'. Together they form a unique fingerprint.

  • Cite this